6 days Ago By Defense World Staff
Wellington Management Group LLP cut its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 91.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission.
The fund owned 810 shares of the medical research company’s stock after selling 9,206 shares during the quarter. Wellington Management Group LLP’s holdings in Bio-Rad Laboratories were worth $266,000 as of its most recent SEC filing. Several other hedge funds also recently modified their holdings of the business.
Strategic Financial Concepts LLC acquired a new position in Bio-Rad Laboratories in the 4th quarter valued at approximately $3,561,000. Lecap Asset Management Ltd. bought a new stake in shares of Bio-Rad Laboratories during the fourth quarter valued at approximately $510,000.
Diversified Trust Co acquired a new position in shares of Bio-Rad Laboratories in the fourth quarter valued at $958,000. DAVENPORT & Co LLC lifted its position in Bio-Rad Laboratories by 48.8% in the fourth quarter.
DAVENPORT & Co LLC now owns 84,677 shares of the medical research company’s stock worth $27,817,000 after purchasing an additional 27,780 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in Bio-Rad Laboratories by 95.
6% during the third quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock worth $14,836,000 after buying an additional 21,669 shares in the last quarter.
65.24% of the stock is owned by institutional investors. Bio-Rad Laboratories Price PerformanceNYSE:BIO opened at $250.
17 on Tuesday. The company has a quick ratio of 4.85, a current ratio of 6.
48 and a debt-to-equity ratio of 0.18. The firm has a market cap of $7.
01 billion, a PE ratio of -3.85 and a beta of 1.12.
Bio-Rad Laboratories, Inc. has a 12 month low of $215.38 and a 12 month high of $387.
99. The company’s 50-day moving average price is $262.86 and its two-hundred day moving average price is $314.
11. Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last announced its earnings results on Thursday, February 13th. The medical research company reported $2.
90 EPS for the quarter, topping the consensus estimate of $2.86 by $0.04.
Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%.
On average, equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.
Wall Street Analyst Weigh InA number of equities analysts have recently issued reports on the stock. Wells Fargo & Company dropped their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.
00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th.
Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company.
Based on data from MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $395.20.
Check Out Our Latest Report on Bio-Rad LaboratoriesAbout Bio-Rad Laboratories (Free Report)Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Featured StoriesFive stocks we like better than Bio-Rad LaboratoriesPros And Cons Of Monthly Dividend StocksWhy NVIDIA Stock Could Soar Despite Wall Street DowngradesWhat Are Dividend Contenders? Investing in Dividend ContendersTop 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldWhy Are Stock Sectors Important to Successful Investing?3 Hot New IPOs Defying the 2025 Market Slump.
